Loading...
 

April - June 2018: 
Volume 31, Issue 2

Click on the image to download the Issue in PDF format.

ARCHIVE

Pneumon 2018, 31(2):67-70, Editorial
Use of Medical Cannabis for Respiratory Diseases
Authors Information

1. Pneumonology Department  of General Hospital of Serres, Greece

References

1. Russo EB. History of cannabis and its preparations in saga, science and sobriquet. Chemistry and Biodiversity 2007; 4:1614-48.

2. Laursen L. Botany: The cultivation of weed. Nature 2015; 525(7570):S4-S5.

3. National Academies of Sciences, Engineering and Medicine. 2017. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press.

4. Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been…The Journal of Head and Face Pain 2015; 55:885-916.

5. National Cancer Institute. 2017. Cannabis and Cannabinoids – Health Professional Version.

6. MacCallum CA, et al. Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine 2018; 49:12-9.

7. Ware MA, et al. Cannabis for the management of pain: Assessment of safety study (COMPASS). J Pain 2015; 16:1233-42.

8. Alon MH, et al. Synthetic cannabinoid induced acute respiratory depression: Case series and literature review. Respiratory Medicine Case Reports 2017; 22:137-41.

9. Tetrault JM, et al. Effects of marijuana smoking on pulmonary function and respiratory complications: A systematic review. Archives of Internal Medicine 2007; 167:221-8.

10. Grassin-Delyle S, et al. Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors. British Journal of Pharmacology 2014; 171:2767-77.

11. Earleywine M, et al. Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduction Journal 2007; 4:11

12. Pickering EE, et al. Cannabinoid effects on ventilation and breathlessness: A pilot study of efficacy and safety. Chronic Respiratory Disease 2011; 8:109-18.

13. Carley DW, et al. Pharmacotherapy of apnea by cannabimimetic enhancement, the PACE clinical trial: effects of Gronabinol in obstructive sleep apnea. Sleep 2018; 41(1).

14. Ramar K, et al. Medical cannabis and the treatment of obstructive sleep apnea: an American Academy of Sleep Medicine position statement. J Clin Sleep Med 2018; 14:679-81.

15. Ribeiro A, et al. Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury. Immunopharmacology and Immunotoxicology 2015; 37:35-41.

16. Karmaus WF, et al. Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice. Journal of Immunotoxicology 2013; 10:321-8.

17. Ribeiro A, et al. Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: Role for the adenosine A2A receptor. European Journal of Pharmacology 2012; 678:78-85.